Part	Performance in Initiating Clinical Research - Quarter 3 (2019/20)  Note: Chelsea and Westminster Hospital NHS Foundation Trust formally acquired West Middlesex University Hospital NHS Foundation Trust on 01 September 2015 and the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission of the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust has been considered to the submission for the former West Middlesex University Hospital NHS Foundation Trust for the former West Middlesex University Hospital NHS Foundation Trust for the former West Middlesex University Hospital NHS Foundation Trust for the former West Middlesex University Hospital NHS Foundation Tr											ation Trust has been subsumed into	
March   Marc	Id	Poroarch	Integrated	Name of Trial			HRA App	oval studies			Date of First	Commonte	Poscope for Dolay correspond to
1965   1965	ū	Ethics Committee	Research Application	Name of That			Approval	Confirmed By		Ready To	Participant	Comments	neasons for Delay Correspond to
Part	151326			invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background	11/06/2018	14/02/2019	26/02/2018	18/02/2019	19/02/2019	20/02/2019	13/05/2019	None	
1979   1979	151327	16/WS/0057	193580	Intervention (Exercise, Nutrition and Anti- inflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in advanced cancer patients undergoing	14/11/2018	07/02/2019	04/08/2016	12/04/2019	18/03/2019	12/04/2019	30/09/2019	Study difficult to recruit - rare patients	Neither
March   Marc	151328	18/SC/0454	249509	Perioperative Ischemic Evaluation-3 Trial	05/02/2019	05/02/2019	16/01/2019	18/03/2019	22/03/2019	19/08/2019	17/09/2019	19/08/19. Site had to recruit new staff to	Both
Part	151329	18/YH/0017	231431		23/08/2018	11/01/2019	01/03/2018	11/01/2019	19/02/2019	03/04/2019	15/04/2019	None	Please Select
2012   2012   2012   2013	151330	18/LO/1537	227239	investigating the efficacy of The Zoo, a form of digital distraction as an analgesic and anxiolytic in	23/04/2018	18/01/2019	18/01/2019	08/05/2019	08/05/2019	09/05/2019	10/05/2019	CRF prior to green light causing delay in	Sponsor
No.   No.	151331	18/LO/2033	252294	hypertension ? a multicentre, randomised	13/02/2019	04/04/2019	10/01/2019	07/05/2019	07/05/2019	06/06/2019	08/08/2019	patients was identified but following green light none were eligible due to	NHS Provider
1.00   1.00	151332	18/LO/1352	243519	Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic	07/09/2018	09/04/2019	03/01/2019	17/04/2019	17/04/2019	23/04/2019	05/06/2019	None	
	151333	16/LO/1318	187932	hepatitis B virus infection to promote HBsAg	25/10/2018	12/04/2019	21/09/2016	07/05/2019	08/05/2019	14/05/2019		None	
No.   Control   Control	151334	19/SC/0122	259342	Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients with Prader-Willi	25/10/2018	08/05/2019	07/05/2019	23/05/2019	23/05/2019	04/06/2019	10/07/2019	None	
Second Control of Transport Processing Places (STARTAL A), AMIL-Confere National Conference for the Control of Transport From Second Control of Transport From Seco	151335	19/LO/0400	250289	Molecular Diagnostics for Hospital-Acquired and Ventilator-Associated Pneumonia on Antimicrobial Stewardship and Patient Outcomes in UK Critical	01/04/2019	02/06/2019	09/04/2019	01/07/2019	02/07/2019	04/07/2019	30/07/2019	None	
1311   1314	151336	17/LO/0621	191390	Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre Randomized	16/11/2018	03/06/2019	22/05/2017	18/06/2019	19/06/2019	05/07/2019		None	
1.560   100,0005   2.2786   100,0005   2.2786   100,0005   100,0	151337	19/LO/0666	261913	over 72 hours following drug intake cessation in	01/01/2019	10/06/2019	10/06/2019	10/06/2019	10/06/2019	12/06/2019	25/06/2019	None	
				Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease. The Late	21/01/2019	21/03/2019	15/01/2019	08/04/2019	18/04/2019	09/05/2019	21/06/2019	difficult to recruit to.	Both
					02/05/2019	05/08/2019	17/07/2019	21/08/2019	10/09/2019	25/09/2019	16/09/2019		
Second	452022	40/05/0452	204547		04/06/2019	07/08/2019	26/07/2019	04/09/2019	06/09/2019	09/09/2019		N	
Apremilar Phases Study on Quality of life in provisions manifestations   27/03/2019   19/02/2019   19/02/2019   1/09/2019				SMOKEFREE	28/08/2019	28/08/2019							
Second   Part   Part				Apremilast Phase4 Study on Quality of life in psoriasis manifestations	27/03/2019	29/08/2019	19/02/2019	12/09/2019	17/09/2019	18/09/2019			
15/03/2037   13/LO/0452   25/0324   CASTLE FIRAL V.I.O   29/07/2019   12/09/2019   13/09/2019	153035	17/EE/0347	201505		19/06/2019	07/09/2019	07/10/2019	26/09/2019	02/10/2019			None	
15333   13/L0/0452   250324	153036	18/EM/0310	239782	IASO	12/09/2019	12/09/2019	17/10/2017	11/10/2019	15/10/2019			None	
15333   19/WA/0005   246081	1526	10/10/0455	2000		09/05/2019	12/09/2019	16/11/2018					Ness	
15700   19/EM/0189   264788   Pembrolitumab with or without olaparib in metastatic sygnamous NSCLC   13/07/2019   13/07/2019   13/07/2019   13/07/2019   16/09/2019   17/10/				CASTLE TRIAL v1.0	29/07/2019	13/09/2019	02/05/2019	01/10/2019	25/09/2019				
Internation												None	
157902   19/KS/0052   25885   Intelligent Operating Room (InOr)   31/05/2019   01/10/2019   11/07/2019   30/10/2019   29/10/2019   30/10/2019   30/10/2019   30/10/2019   Please Select     157903   19/EM/0220   265213   Switching to DTG/3TC in virologically suppressed HIV-infected adults   18/10/2019   11/09/2019   11/09/2019   11/10/2019   11/10/2019   15/11/2019   Target of 2 patients, to be recruited by Please Select     157910   19/EM/0258   266702   Fluids Exclusively Enteral from Day 1 (FEED1)   18/10/2019   01/11/2019   13/09/2019   02/12/2019   04/12/2019   13/12/2019   13/12/2019   Please Select     157911   19/L0/1270   261294   Cerclage after full dilatation caesarean section   15/08/2019   07/11/2019   21/11/2019   21/11/2019   21/11/2019   21/12/2019   09/12/2019   09/12/2019   Please Select     157913   19/L0/0773   263695   Pembrolizumab + Olaparib It treatment of Metastatic Nonsquamous NSCLC   44/01/2019   19/11/2019   19/11/2019   18/09/2019   03/12/2019   03/12/2019   03/12/2019   15/10/2020   15/10				metastatic squamous NSCLC									
IN-infected adults   11/05/2020.   11/05/2				with DCCR							11/10/2019		
157910 19/EM/0258 266702 Fluids Exclusively Enteral from Day 1 (FEED1) 18/10/2019 01/11/2019 13/09/2019 02/12/2019 04/12/2019 13/12/2019 04/12/2019 05/12/2019 Please Select  157911 19/EM/083 25173 Epiprotect vs Suprathel vs Biobrane for SPT/DD 05/04/2019 21/11/2019 21/11/2019 21/11/2019 02/12/2019 09/12/2019 09/12/2019 09/12/2019 Please Select  157912 19/EM/083 25173 Epiprotect vs Suprathel vs Biobrane for SPT/DD 05/04/2019 21/11/2019 21/11/2019 21/11/2019 02/12/2019 09/12/2019 09/12/2019 Please Select  157913 19/L0/0773 263695 Pembrolitumab + Olaparib 1L treatment of Metastatic Nonsquamous NSCLC 12/09/2019 19/10/2018 02/12/2019 03/12/2019 03/12/2019 03/12/2019 15/10/2002 02/12/2019 03/	157909	19/EM/0220	265213		30/09/2019	09/10/2019	11/09/2019	10/10/2019	11/10/2019	15/11/2019			Please Select
157912 19/NW083 25177 Epiprotect vs Suprathel vs Biobrane for SPT/DD 05/04/2019 21/11/2019 21/11/2019 21/16/2019 02/12/2019 09/12/2019 09/12/2019 Please Select  157913 19/L0/0773 263695 Pembrolizumab + Olaparib IL treatment of Metastatic Nonsiquamous NSCLC 24/01/2019 22/11/2019 07/08/2019 18/09/2019 02/12/2019 03/12/2019 03/12/2019 15/10/2020 Target of 3 patients, to be recruited by Please Select  157914 18/NE/0296 244867 CALIBRE Study 12/09/2019 19/12/2019 19/10/2018 Confirmed in Jan 2020 so will be reported Please Select	157910	19/EM/0258	266702		18/10/2019	01/11/2019	13/09/2019	02/12/2019	04/12/2019	13/12/2019		11/05/2020.	Please Select
Sums	157911	19/LO/1270	261294	Cerclage after full dilatation caesarean section	15/08/2019	07/11/2019	20/09/2019	08/10/2019	19/11/2019	25/11/2019	05/12/2019		Please Select
157913 19/L0/0773 263695 Pembrolizumab + Olaparib 1L treatment of Metastatic Nonsquamous NSCLC 24/01/2019 22/11/2019 07/08/2019 18/09/2019 02/12/2019 03/12/2019 17arget of 3 patients, to be recruited by 15/10/2020 15/10/2020 15/10/2020 Please Select	157912	19/NW0483	251737		05/04/2019	21/11/2019	21/11/2019	21/06/2019	02/12/2019	09/12/2019			Please Select
	157913	19/LO/0773	263695	Pembrolizumab + Olaparib 1L treatment of	24/01/2019	22/11/2019	07/08/2019	18/09/2019	02/12/2019	03/12/2019			Please Select
in Q4 report.	157914	18/NE/0296	248487	CALIBRE Study	12/09/2019	19/12/2019	19/10/2018						Please Select